Total Payments
$2,521
2024 Payments
$1,072
Companies
29
Transactions
74
Medicare Patients
13,267
Medicare Billing
$5.3M
Payment Breakdown by Category
Food & Beverage$2,393 (95.0%)
Education$127.11 (5.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,393 | 70 | 95.0% |
| Education | $127.11 | 4 | 5.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $337.01 | 8 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $293.46 | 9 | $0 (2024) |
| PFIZER INC. | $226.44 | 9 | $0 (2024) |
| GENZYME CORPORATION | $218.81 | 2 | $0 (2024) |
| Celgene Corporation | $176.78 | 6 | $0 (2024) |
| Gilead Sciences, Inc. | $169.24 | 5 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $165.44 | 3 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $137.03 | 2 | $0 (2024) |
| Genentech USA, Inc. | $121.40 | 2 | $0 (2023) |
| PharmaEssentia USA Corporation | $83.81 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,072 | 40 | Lilly USA, LLC ($170.67) |
| 2023 | $900.24 | 26 | PFIZER INC. ($174.97) |
| 2022 | $110.42 | 1 | E.R. Squibb & Sons, L.L.C. ($110.42) |
| 2021 | $11.92 | 1 | Gilead Sciences, Inc. ($11.92) |
| 2019 | $289.05 | 3 | Genentech USA, Inc. ($102.40) |
| 2018 | $136.88 | 3 | Gilead Sciences, Inc. ($116.57) |
All Payment Transactions
74 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $27.75 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $23.40 | General |
| Category: Oncology | ||||||
| 11/12/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $121.84 | General |
| Category: Oncology | ||||||
| 11/11/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $41.41 | General |
| 11/06/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $17.94 | General |
| Category: Oncology | ||||||
| 11/04/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $20.21 | General |
| 10/30/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $19.02 | General |
| Category: Oncology | ||||||
| 10/28/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $18.62 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 10/23/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $26.17 | General |
| Category: ONCOLOGY | ||||||
| 10/21/2024 | Incyte Corporation | MONJUVI (Drug) | Food and Beverage | Cash or cash equivalent | $25.12 | General |
| Category: Oncology | ||||||
| 09/30/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $21.55 | General |
| Category: Oncology | ||||||
| 09/16/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $21.85 | General |
| Category: ONCOLOGY | ||||||
| 09/11/2024 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug) | Food and Beverage | In-kind items and services | $20.29 | General |
| Category: Oncology | ||||||
| 09/04/2024 | Myriad Genetic Laboratories, Inc. | MYRISK (Device) | Food and Beverage | In-kind items and services | $25.21 | General |
| Category: ONCOLOGY | ||||||
| 08/26/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $18.32 | General |
| Category: Oncology | ||||||
| 08/21/2024 | Alnylam Pharmaceuticals Inc. | ONPATTRO (Drug) | Food and Beverage | In-kind items and services | $28.79 | General |
| Category: Genetic Disease | ||||||
| 08/19/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $21.66 | General |
| Category: Iron Deficiency Anemia | ||||||
| 08/14/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $26.61 | General |
| Category: Oncology | ||||||
| 08/13/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $21.51 | General |
| 08/12/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $24.16 | General |
| Category: Oncology | ||||||
| 08/07/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $32.88 | General |
| 07/24/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $31.30 | General |
| 07/23/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Food and Beverage | Cash or cash equivalent | $70.13 | General |
| Category: Oncology | ||||||
| 07/08/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $16.82 | General |
| Category: Oncology | ||||||
| 06/12/2024 | Alnylam Pharmaceuticals Inc. | ONPATTRO (Drug) | Food and Beverage | In-kind items and services | $18.79 | General |
| Category: Genetic Disease | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 54 | 3,108 | 85,852 | $2.7M | $917,504 |
| 2022 | 43 | 2,854 | 102,600 | $4.2M | $1.4M |
| 2021 | 51 | 3,387 | 138,351 | $5.0M | $1.6M |
| 2020 | 58 | 3,918 | 154,770 | $4.5M | $1.4M |
Total Patients
13,267
Total Services
481,573
Medicare Billing
$5.3M
Procedure Codes
207
All Medicare Procedures & Services
207 procedure records from CMS Medicare Utilization — Page 1 of 9
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 17 | 11,800 | $1.5M | $496,032 | 34.2% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 21 | 5,100 | $243,600 | $92,723 | 38.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 425 | 853 | $172,274 | $78,604 | 45.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 498 | 606 | $82,026 | $37,031 | 45.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 81 | 369 | $120,546 | $35,992 | 29.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 146 | 216 | $60,368 | $28,769 | 47.7% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 46 | 52,530 | $111,180 | $20,618 | 18.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 118 | 118 | $48,622 | $19,424 | 39.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 106 | 106 | $34,739 | $13,146 | 37.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 64 | 75 | $28,975 | $10,249 | 35.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 58 | 155 | $21,383 | $9,872 | 46.2% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2023 | 11 | 1,520 | $32,640 | $9,402 | 28.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 82 | 169 | $26,032 | $8,125 | 31.2% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 14 | 57 | $31,068 | $7,881 | 25.4% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 34 | 137 | $20,825 | $6,820 | 32.8% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 61 | 266 | $19,642 | $5,876 | 29.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 20 | 42 | $8,295 | $3,916 | 47.2% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 23 | 69 | $11,890 | $3,398 | 28.6% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 127 | 281 | $8,430 | $2,908 | 34.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 130 | 287 | $4,018 | $2,411 | 60.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 58 | 224 | $11,243 | $2,290 | 20.4% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 122 | 294 | $6,468 | $2,237 | 34.6% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 30 | 87 | $6,024 | $1,912 | 31.7% |
| 96411 | Administration of additional new drug or substance into vein using push technique | Office | 2023 | 13 | 44 | $6,466 | $1,888 | 29.2% |
| 96523 | Irrigation of implanted venous access drug delivery device | Office | 2023 | 67 | 101 | $6,071 | $1,460 | 24.0% |
About Dr. Galina Vugman, MD
Dr. Galina Vugman, MD is a Hematology & Oncology healthcare provider based in Sarasota, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1093891673.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Galina Vugman, MD has received a total of $2,521 in payments from pharmaceutical and medical device companies, with $1,072 received in 2024. These payments were reported across 74 transactions from 29 companies. The most common payment nature is "Food and Beverage" ($2,393).
As a Medicare-enrolled provider, Vugman has provided services to 13,267 Medicare beneficiaries, totaling 481,573 services with total Medicare billing of $5.3M. Data is available for 4 years (2020–2023), covering 207 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology
- Location Sarasota, FL
- Active Since 10/27/2006
- Last Updated 08/12/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1093891673
Products in Payments
- VERZENIO (Drug) $126.49
- SARCLISA (Biological) $121.84
- TAGRISSO (Drug) $117.71
- XTANDI (Drug) $115.51
- PIQRAY (Drug) $112.48
- Zydelig (Drug) $110.49
- GAZYVA (Biological) $102.40
- JEVTANA (Drug) $96.97
- JAYPIRCA (Drug) $94.68
- PLUVICTO (Drug) $92.39
- BESREMI (Drug) $83.81
- REBLOZYL (Biological) $79.80
- MONJUVI (Drug) $70.38
- MYRISK (Device) $69.30
- KISQALI (Drug) $68.30
- IBRANCE (Drug) $60.62
- ONPATTRO (Drug) $47.58
- VYNDAQEL (Drug) $31.40
- AVASTIN (Drug) $27.34
- OPDIVO (Biological) $26.61
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Sarasota
Steven Mamus, M.d, M.D
Hematology & Oncology — Payments: $31,342
Hematology & Oncology $31,342
Dr. Manjesh Lingamurthy, M.d, M.D
Hematology & Oncology — Payments: $24,000
Hematology & Oncology $24,000
Dr. Andrew Marple, M.d., Ph.d, M.D., PH.D
Hematology & Oncology — Payments: $2,269
Hematology & Oncology $2,269
Rodrigo Garcia, M.d, M.D
Hematology & Oncology — Payments: $203.42
Hematology & Oncology $203.42
Dr. Raymond Markham, M.d, M.D
Hematology & Oncology — Payments: $23.93
Hematology & Oncology $23.93
Hubert Gerrry, M.d, M.D
Hematology & Oncology
Hematology & Oncology